Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Foundation Medicines

- PMLiVE

AZ showcases data for next-generation PARP inhibitor AZD5305

Early preclinical data presented at virtual American Association of Cancer Research meeting

- PMLiVE

Sanofi pays $160m upfront to acquire Tidal Therapeutics

French pharma company's acquisition of pre-clinical stage biotech includes mRNA-based research platform

Advancing Precision Medicine in Oncology

Jerome Madison, Host of The Precision Medicine Podcast, shares his leadership lessons and tips for building and training new sales teams in the era of precision medicine. He also dives...

Impetus Digital

- PMLiVE

New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement

Regulators in Canada and Germany have reportedly placed new restrictions on vaccine

- PMLiVE

Oxford University to investigate nasal spray delivery of AZ-partnered COVID-19 vaccine

Early-stage trial will enrol 30 healthy volunteers aged 18-40

- PMLiVE

EMA updates product information for AZ COVID-19 vaccine

PRAC reaffirms opinion that AZ vaccine's efficacy outweighs very rare likelihood of developing a blood clotting disorder

- PMLiVE

AZ publishes primary analysis for COVID-19 vaccine, showing slightly lower efficacy of 76%

AZ previously announced vaccine efficacy of 79% in US-based trial

- PMLiVE

Efficacy data from US trial for AZ/Oxford vaccine raises concerns over possible ‘incomplete view’

AZ will engage ‘immediately’ with DSMB to share primary analysis with up-to-date efficacy data

- PMLiVE

AZ/Oxford COVID-19 vaccine hits primary efficacy endpoint in US-based trial

Specific review of thrombotic events found no increased risk of thrombosis associated with vaccine

- PMLiVE

EMA review confirms AZ/Oxford’s COVID-19 vaccine is safe and effective

EU regulator said that the vaccine is not associated with an increase in the overall risk of blood clots

- PMLiVE

Benefits of AZ COVID-19 vaccine ‘continue’ to outweigh risks, says EMA’s executive director

EU regulator is expected to publish findings from its investigation on Thursday

- PMLiVE

AstraZeneca to supply US government with 500,000 additional doses of its COVID-19 antibody

AZD7442 is a long-acting antibody combination that could help to prevent and treat COVID-19

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links